Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2022, which ended April 2, 2022, are available on its Investor Relations website.